Lercanidipine Accord

Lercanidipine, the active ingredient in Lercanidipine Accord, is a dihydropyridine calcium channel blocker presented as an oral tablet for oral use. It is prescribed to lower elevated blood pressure in adult patients with hypertension. GNH USA supplies Lercanidipine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is used within the antihypertensive drug class to manage high blood pressure conditions. Hypertension: reduces systolic and diastolic blood pressure to target levels. Essential hypertension: provides long‑term control of primary high blood pressure. Isolated systolic hypertension: lowers elevated systolic pressure in older adults.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: warmth and redness of the skin. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness. - Tachycardia: increased heart rate. - Fatigue or general weakness.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, or throat. - Severe hypotension: markedly low blood pressure. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, pruritus, or anaphylaxis. - Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Hepatic impairment: use with caution; dose adjustment may be required. - Elderly patients: start at the lowest effective dose and monitor closely. - Known hypersensitivity: discontinue if allergic reactions occur. - Concomitant antihypertensives: adjust doses to prevent additive blood pressure lowering. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Other potent antihypertensives: risk of severe hypotension. - Grapefruit juice: can elevate drug concentration.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Diuretics: may enhance blood pressure reduction. - Beta‑blockers: additive cardiovascular effects. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response. - Lithium: monitor lithium levels for potential increase.